Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs

Affiliation auteurs!!!! Error affiliation !!!!
TitreIncidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs
Type de publicationJournal Article
Year of Publication2018
AuteursNahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, de Ledinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki J-P, Zarski J-P, Riachi G, Cales P, Peron J-M, Alric L, Bourliere M, Mathurin P, Blanc J-F, Abergel A, Serfaty L, Mallat A, Grange J-D, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Roudot-Thoraval F, Audureau E, Grp ANRSCO12 CirVi
JournalGASTROENTEROLOGY
Volume155
Pagination1436+
Date PublishedNOV
Type of ArticleArticle
ISSN0016-5085
Mots-clésANRS, CirVir, liver cancer, Risk factors
Résumé

{BACKGROUND & AIMS: Retrospective studies have found an unexpectedly high incidence of hepatocellular carcinoma (HCC) among patients with hepatitis C virus (HCV)-associated cirrhosis who received direct-acting antiviral (DAA) agents. We analyzed data from the ANRS CO12 CirVir cohort to compare the incidence of HCC in patients with cirrhosis who received DAA therapy vs patients treated with interferon (IFN). METHODS: Data were collected from 1270 patients with compensated biopsy-proven HCV-associated cirrhosis recruited from 2006 through 2012 at 35 centers in France. For descriptive purpose, patients were classified as follows: patients who received DAA treatment (DAA group
DOI10.1053/j.gastro.2018.07.015